Surgery for high-risk prostate cancer

摘要

Although most men with high-risk prostate cancer are offered radiotherapy with hormone treatment as a primary treatment option, there is no evidence to suggest that this has any advantages over surgery. Prostate cancer is the commonest malignancy occurring in men in the UK, with 35000 new cases being diagnosed per year and 10000 deaths each year, which roughly equates to one death every hour. High-risk prostate cancer (HRPC) is associated with the highest rates of treatment failure, need for secondary intervention, metastasis and death among patients diagnosed with prostate cancer.